---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-24-000099"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:14:07.650732+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aurinia restructures board: 3 directors resign, Kevin Tang appointed, CEO Greenleaf stays

## Summary
- Board accepted conditional resignations of Daniel Billen, Hector MacKay-Dunn, and Brinda Balakrishnan, effective Sept 9, 2024.
- CEO Peter Greenleaf remains director; Board cited exceptional circumstances for rejecting his conditional resignation.
- Kevin Tang, President of Tang Capital Management, appointed as director effective Sept 12, 2024.
- Board reduced from 9 to 7 members; Amended and Restated Bylaws now authorize Board to set director count.

## SEC filing metadata
- accession: 0001600620-24-000099
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/auph-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-24-000099
- JSON: https://secwatch.observer/filing/0001600620-24-000099.json
- Plain text: https://secwatch.observer/filing/0001600620-24-000099.txt

## Key facts
- Executive change
  Kevin Tang was appointed as Director at Aurinia Pharmaceuticals Inc..
  - Action: appointed
  - Role: Director
  source text: Effective September 12, 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm
- Executive change
  Brinda Balakrishnan resigned as Director at Aurinia Pharmaceuticals Inc..
  - Action: resigned
  - Role: Director
  source text: the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm
- Executive change
  R. Hector MacKay-Dunn resigned as Director at Aurinia Pharmaceuticals Inc..
  - Action: resigned
  - Role: Director
  source text: the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm
- Executive change
  Daniel G. Billen resigned as Director at Aurinia Pharmaceuticals Inc..
  - Action: resigned
  - Role: Director
  source text: the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.